Abstract
Opioid receptors and opioid peptides constitute the endogenous opioid system. The most relevant function of the opioid system seems to be the inhibitory modulation of nociceptive information at supraspinal, spinal and peripheral sites, although it is also implicated in the modulation of many other processes in the body. Centrally acting plant opiates, such as morphine, are the most frequently used analgesics for the relief of severe pain, even though their undesired side-effects are serious limitation to their usefulness. Opioid peptides have the potential to be pharmaceutical agents for the treatment of pain, devoid of side-effects accompanying morphine. Unfortunately, peptides are generally hydrophilic compounds that will not enter the central nervous system via passive diffusion, due to the existence of the blood-brain barrier. Peptides are also easily degraded by proteolytic enzymes which further reduces their therapeutic value. Therefore, the design of peptide analogs based on the sequence of endogenous opioid peptides must be focused on increasing bioavailability and enhancing brain uptake.
Current Pharmaceutical Design
Title: Development of Opioid Peptide Analogs for Pain Relief
Volume: 16 Issue: 9
Author(s): A. Janecka, R. Perlikowska, K. Gach, A. Wyrebska and J. Fichna
Affiliation:
Abstract: Opioid receptors and opioid peptides constitute the endogenous opioid system. The most relevant function of the opioid system seems to be the inhibitory modulation of nociceptive information at supraspinal, spinal and peripheral sites, although it is also implicated in the modulation of many other processes in the body. Centrally acting plant opiates, such as morphine, are the most frequently used analgesics for the relief of severe pain, even though their undesired side-effects are serious limitation to their usefulness. Opioid peptides have the potential to be pharmaceutical agents for the treatment of pain, devoid of side-effects accompanying morphine. Unfortunately, peptides are generally hydrophilic compounds that will not enter the central nervous system via passive diffusion, due to the existence of the blood-brain barrier. Peptides are also easily degraded by proteolytic enzymes which further reduces their therapeutic value. Therefore, the design of peptide analogs based on the sequence of endogenous opioid peptides must be focused on increasing bioavailability and enhancing brain uptake.
Export Options
About this article
Cite this article as:
Janecka A., Perlikowska R., Gach K., Wyrebska A. and Fichna J., Development of Opioid Peptide Analogs for Pain Relief, Current Pharmaceutical Design 2010; 16(9) . https://dx.doi.org/10.2174/138161210790963869
DOI https://dx.doi.org/10.2174/138161210790963869 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interactions Between Cholinergic and Fibroblast Growth Factor Receptors in Brain Trophism and Plasticity
Current Protein & Peptide Science The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Comparison of Glucocorticoid Receptor- and Epigenetically Regulated Genes in Proliferating Versus Growth-Arrested Neuro-2a Cells
CNS & Neurological Disorders - Drug Targets Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Mechanism of Oxidative Broncho-Epithelial Cell Damage with Reference to Gas Phase Cigarette Smoke
Mini-Reviews in Organic Chemistry The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets Commentary: Intravenous Immunoglobulin (IVIG) Therapy for Patients with Langerhans Cell Histiocytosis (LCH)-Related Neurodegenerative Diseases of the CNS
CNS & Neurological Disorders - Drug Targets Clinical Application of Ghrelin
Current Pharmaceutical Design Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Aging, Mitochondria and Male Reproductive Function
Current Aging Science